“Investments, research and innovation”, was the theme of a conference organized in Tripoli by the Panhellenic Union of Pharmaceutical Industries.
The event was attended by the Minister of Health Adonis Georgiadis, the general secretary of private investments of the Ministry of Development, Vicky Loizou, the Member of Parliament of Arcadia Kostas Vlasis, Dimitris Ptochos (regional governor of Peloponnese), the mayors of Arcadia, Vassilis Kontozamanis (advisor to the Prime Minister on of Health, former Ministry of Health), presidents and representatives of institutional, scientific and productive bodies in the region, representatives of associations, unions, the management of the Union of Pharmaceutical Industries, the senior executives of the three (DEMO, Elpen group, ) companies that invest in Tripoli, but also health professionals.
Today’s event highlights the great added value of the Greek pharmaceutical industry to the Greek economy and society. An industrial area, a city, a prefecture, are revitalized by the large investments of the Greek pharmaceutical industry. Throughout the country, we create thousands of direct and indirect jobs and cover millions of Greeks with domestically produced medicines. With the completion of these investments, we will address shortages in many essential medicines. We give hope and perspective to many young people. We prove that Greece can be the center of drug production for the whole of Europe”, said in his greeting, among others, the president of PEF, Theodoros Tryphon (ELPEN).
Dimitris Demos (vice-president of PEF, DEMO), in his speech, proceeded with a presentation regarding the contribution of the Greek pharmaceutical industry to research and innovation, saying the following: “Through innovation, new therapeutic solutions are promoted. However, the spread of these solutions, globally and especially in countries that cannot afford to buy increasingly expensive drugs, comes through the generics industry, which not only ensures affordable medicine in a large part of the world following the end of the protection regime, but through marginal innovation actions, it improves the original product, in order to create ease of use and increase patient compliance”.
At the event, reference was made (Faie Kosmopoulou, general director of PEF), to the investments of the domestic pharmaceutical industry that are being implemented for the period 202 – 2026.
These are 10 new factories, 22 new production units and 14 new research structures.
At the event of P.E.F. the Minister of Health Adonis Georgiadis also attended and spoke
Aristotelis Lymberopoulos (DEMO), spoke regarding the company’s investments in Tripoli.
He said, characteristically: “For the first time in Greece, raw materials for drugs, but also final pharmaceutical products, of chemical origin, will be produced in Tripoli. With the completion of the projects, this company will be among the 3 largest penicillin and oncology drug production units in Europe. With the products that will be produced in Tripoli, the company will be able to cover 34% of the European Union’s needs for penicillins and 35% for oncology drugs. DEMO is contributing to the upgrading of Arcadia, since more than 1,000 jobs will be created over a period of 10 years. Tripoli is being promoted to a European center of medicine ΄΄
Christos Sotiriou, vice president of the board of directors and managing director of WIN MEDICA, speaking regarding the investment in Tripoli, said the following: “The construction of the new production unit in Tripoli transforms it from a purely commercial to a productive company. The new unit will have a total investment of 50 million euros and will create 250 jobs (direct and indirect). The benefits of the investment are expected to exceed 100 million euros. With the oncology drugs that the new unit will produce, 50% of the needs of Greek patients will be met, in 11 basic oncology drugs. The company, at the same time, has already concluded agreements and plans to export the pharmaceutical preparations to more than 40 countries in Europe and Asia”.
Marios Katsikas (president and CEO of the company that will invest in Tripoli, FARAN), announced the company’s decision to invest in Tripoli. “We have quintupled the turnover of the company in the last 5 years, moving forward with our next plans. We will build a modern research and production unit for injectable and future biotechnological drugs, with a total area of 12,000 sq.m., which will be built on a plot of 36,000 sq.m. at the Tripoli University of Applied Sciences. The unit will initially develop sterile filling and packaging lines for parenteral preparations, small volume, in liquid and lyophilized form, in vials, cartridges and pre-filled syringes, and in addition, biotechnological medicines are planned to be produced in the same facility in the future. The unit will follow the highest standards, introducing new standards in technological equipment and production processes, and it is planned to be certified by the EMA and by the FDA, so that it can have its products and services on the international market.
At the well-organized event – presentation of Tripoli, greetings were addressed by the Minister of Health, the general secretary of private investments, the regional governor of Peloponnese, the mayor of Tripoli, the MP Kostas Vlasis.
The PEF event, in Tripoli and in the event hall of the Music School, was also attended by former PEF officials.
Read also:
Minimum wage: Up to 1,079 euros over three years – Which benefits are increasing and how much following the new increase
Earthquake in Strofades: Worried Achaia, reached as far as Italy – Patras Seismology: “We don’t know the main tremor”
European elections: Mitsotakis tour in Kalavryta – Officials of the parties from Achaia speak to “P”
Topic in Daily Mail Roula Pispirigou: “Posed as a loving mother and killed her quadriplegic daughter with ketamine”
Instant update with all the news now and via WhatsApp – See here
#Tripoli #developing #strong #hub #domestic #drug #production